期刊文献+

保心康与常规药物合用对慢性心衰大鼠心功能、心肌ATP酶活性的影响

Baoxinkang Formula Combining with Conventional Medicine Therapy in Influencing Cardiac Function and Myocardial ATPase Activity in Rats with Chronic Heart Failure
下载PDF
导出
摘要 目的观察保心康与常规药物疗法合用对慢性心力衰竭(CHF)大鼠模型的心功能及心肌三磷酸腺苷(ATP)酶活性的影响。方法 SD大鼠随机分为假手术组、模型组、保心康组、常规疗法组、常规疗法+保心康组、常规疗法+曲美他嗪组。采用腹主动脉缩窄术复制CHF大鼠模型。用保心康(1020 mg·kg-1)联合常规疗法(美托洛尔10 mg·kg-1、卡托普利5 mg·kg-1、地高辛0.0225 mg·kg-1)治疗6周,以心脏彩超测定大鼠心功能,并检测心肌组织中Na+-K+-ATP酶、Ca2+-Mg2+-ATP酶活性。结果保心康对CHF大鼠心脏增大有一定的制抑作用(P<0.01,P<0.05),并提高Ca2+-Mg2+-ATP酶的活性(P<0.05)。保心康与常规药物联用在抑制心脏增大、减慢心率、保护射血分数和心输出量方面优于单纯使用常规药物(P<0.01,P<0.05);心肌Na+-K+-ATP酶、Ca2+-Mg2+-ATP酶活明显高于模型组(P<0.01)。结论保心康对CHF大鼠心功能有一定的改善作用,保心康联用常规药物对改善心衰大鼠心功能有一定的增效作用,保心康对CHF大鼠的治疗作用可能与提高Ca2+-Mg2+-ATP酶活性有关。 Objective This research is to figure out whether the combination of Baoxinkang formula and conventional medicine therapy is better than conventional medicine therapy only in preservation of ATPase activity in chronic heart failure rat model. Methods Sprague-Dawley rats were randomly divided into 6 groups, the Baoxinkang group, conventional medicine therapy group, the Baoxinkang and conventional medicine therapy group, the trimetazidine and conventional medicine therapy group, control group and sham-operation group. Abdominal aortic constriction was performed to induce chronic heart failure. Baoxinkang( 1020 mg·kg-1) in combination with conventional medicine therapy (Metoprolol 10 mg·kg-1, Captopril 5mg·kg-1, Digoxin 0.0225 mg·kg-1) was administrated for 6 weeks. Echocardiography was performed to evaluate the cardiac function. The activity of Na+-K+-ATPase(NKA), Ca2+-Mg2+ -ATPase (CMA) was examined by spectrometry. Results Echocardiography showed that either comparing with the control group or conventional medicine therapy group, Baoxinkang+conventional medicine therapy group had improved enlarged heart, higher ejection fraction, higher cardiac output and lower heart rate. Myocardial ATPase activity in Baoxinkang+conventional medicine therapy group were higher than those in the control group. Comparing with controlgroup, Baoxinkang group has higher CMA activity, but similar NKA activity. No signifieant difference was observed in ATPase activity between Baoxinkang+conventional medicine therapy group and conventional medicine therapy group. Conclusion Baoxinkang formula could provide better protection to the activity of CMA, modulate the consumption of ATP to improve the cardiac fimction. The synergistic protection of Baoxinkang formula in combination with conventional medicine therapy may not eompletely cause by the preservation of ATPase activity. How does the Baoxinkang formula protect the activity of myocardial NKA and CMA needs further study.
出处 《中药新药与临床药理》 CAS CSCD 北大核心 2014年第3期299-302,共4页 Traditional Chinese Drug Research and Clinical Pharmacology
基金 广东省科技计划项目(2011B031700073) 广东省临床用药研究基金-施慧达心血管用药研究基金(2013X30)
关键词 保心康 慢性心力衰竭 Can-Mg2+-ATP酶 Can+-Mg2+-ATP酶 Baoxinkang formula Chronic Heart Failure Na+-K+-ATPase Ca2+-Mg2+-ATPase
  • 相关文献

参考文献14

  • 1Schwinger RHG, Wang J, Frank K, et al. Reduced sodium pump alpha1, alpha3, and heta1-isnform protein levels and Na^+-K^+-ATPase activity but unchanged Na^+-Ca^2+ exchanger protein levels in human heart failing[J]. Circulation, 1999, 99: 2015.
  • 2Zahler R, Gilmore-Hebert M, Sun W, et al. Na^+-K^+-ATPase isotherm gene expression in normal and hypertrophied dog heart[J]. Basic Res Cardiol, 1996, 91: 256-266.
  • 3Norgaard A, Bagger JP, Bjerregaard P, et al. Relation of left ventric- ular function and Na, K-pump concentration in suspected idiopathic dilated cardiomyopathy[J]. Am J Cardiol, 1988, 61 : 1312-1315.
  • 4Ishino K, Botker HE, Clausen T, et al. Myocardial adenine nu- cleotides, glycogen, and Na^+, K^+-ATPase inpatients with idiopathic dilated cardiomyapathy requiring mechanical circulatory support[J]. Am J Cardiol, 1999, 83: 396-399.
  • 5Chu G, Carr AN, Young KB, et al. Enhanced myocyte contractility and Ca^2+ handling in a calcineurin transgenic model of heart failure[J]. Cardiovasc Res, 2002, 54(1 ): 105-116.
  • 6Pagani ED, Alousi AA, Grant AM, et al. Changes in myofibrillar content and Mg-ATPase aetivity in ventricular tissues from patients with heart failure caused by coronary artery disease, cardiomyopathy, or mitral valve insufficiency[J]. Cire Res, 1988, 63: 380-385.
  • 7黄衍寿,冼绍祥,丁有钦,卢丽萍,陈宇鹏,吴辉.保心康治疗气阳虚型充血性心力衰竭的临床研究[J].中药新药与临床药理,2000,11(5):261-265. 被引量:20
  • 8陈宇鹏,冼绍祥,黄衍寿.保心康对家兔实验性心功能不全动物模型的药效学研究[J].广州中医药大学学报,2002,19(1):36-39. 被引量:9
  • 9黄衍寿,冼绍祥,杨慧,周名璐,陈芝喜.保心康对心肌肥大型心力衰竭大鼠血管平滑肌环核苷酸水平的影响[J].广州中医药大学学报,2002,19(4):302-304. 被引量:7
  • 10冼绍祥,杨忠奇,汪朝辉,等.心力衰竭中西医结合研究基础与临床[M].上海:上海科技出版社,2011:110-116.

二级参考文献14

共引文献32

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部